Crossmark

Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study

Crossref DOI link: https://doi.org/10.1186/s13075-023-03182-9

Published Online: 2023-10-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Luchetti Gentiloni, Michele Maria

Paci, Valentino

Carletto, Antonio

Zabotti, Alen

Ramonda, Roberta

Chimenti, Maria Sole

Dagna, Lorenzo

Luciano, Nicoletta

Piccinelli, Anna

Giovannini, Ivan

Striani, Giovanni

Boffini, Nicola

Sandri, Gilda

Possemato, Niccolò

Pantano, Ilenia

Benfaremo, Devis

Salvarani, Carlo

Ciccia, Francesco

Selmi, Carlo

Moroncini, Gianluca
License Information

Text and Data Mining valid from 2023-10-11

Version of Record valid from 2023-10-11
More Information

Article History

Received: 5 August 2023

Accepted: 25 September 2023

First Online: 11 October 2023

Declarations

:

: The study is observational, and the patients were treated following current medical practice. The study was performed according to the Helsinki Declaration, patients provided written informed consent for data collection and analysis. The study was performed following the approval of the ethical committee of the Marche Polytechnic University and the Azienda Ospedaliero Universitaria delle Marche”, Ancona, Italy (n. 3067).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below